Verona Pharma (VRNA) stock: Winston Score and insider trades

Verona Pharma is a biotechnology company focused on developing treatments for chronic respiratory diseases. Its lead product, Ohtuvayre (ensifentrine), is a dual-action bronchodilator approved in the US for the maintenance treatment of chronic obstructive pulmonary disease (COPD). COPD affects millions of people worldwide, and Ohtuvayre works through a novel mechanism that combines anti-inflammatory and bronchodilator effects in a single inhaled therapy. Verona generates revenue from US sales of Ohtuvayre, which launched commercially in 2024. The company is headquartered in London but operates primarily in the United States, where it has built its own commercial infrastructure. Its competitive moat rests on Ohtuvayre's first-in-class mechanism of action, offering a differentiated option in a market dominated by older drug classes. Key growth drivers include expanding Ohtuvayre's adoption among pulmonologists and primary care physicians, as well as pursuing additional respiratory indications, though the company remains unprofitable as it invests heavily in commercialization and development.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-15.